Abstract
Background Guidelines recommend annual surveillance imaging after diagnosis of ductal carcinoma in situ (DCIS). Guideline adherence has not been characterized in a contemporary cohort. Purpose To identify uptake and determinants of surveillance imaging in women who underwent treatment for DCIS. Materials and Methods A stratified random sample of women who underwent breast-conserving surgery for primary DCIS between 2008 and 2014 was retrospectively selected from 1330 facilities in the United States. Imaging examinations were recorded from date of diagnosis until first distant recurrence, death, loss to follow-up, or end of study (November 2018). Imaging after treatment was categorized into 10 12-month periods starting 6 months after diagnosis. Primary outcome was per-period receipt of asymptomatic surveillance imaging (mammography, MRI, or US). Secondary outcome was diagnosis of ipsilateral invasive breast cancer. Multivariable logistic regression with repeated measures and generalized estimating equations was used to model receipt of imaging. Rates of diagnosis with ipsilateral invasive breast cancer were compared between women who did and those who did not undergo imaging in the 6-18-month period after diagnosis using inverse probability-weighted Kaplan-Meier estimators. Results A total of 12 559 women (median age, 60 years; IQR, 52-69 years) were evaluated. Uptake of surveillance imaging was 75% in the first period and decreased over time (P < .001). Across the first 5 years after treatment, 52% of women participated in consistent annual surveillance. Surveillance was lower in Black (adjusted odds ratio [OR], 0.80; 95% CI: 0.74, 0.88; P < .001) and Hispanic (OR, 0.82; 95% CI: 0.72, 0.94; P = .004) women than in White women. Women who underwent surveillance in the first period had a higher 6-year rate of diagnosis of invasive cancer (1.6%; 95% CI: 1.3, 1.9) than those who did not (1.1%; 95% CI: 0.7, 1.4; difference: 0.5%; 95% CI: 0.1, 1.0; P = .03). Conclusion Half of women did not consistently adhere to imaging surveillance guidelines across the first 5 years after treatment, with racial disparities in adherence rates. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Rahbar and Dontchos in this issue.
| Original language | English |
|---|---|
| Article number | e221210 |
| Pages (from-to) | 221210 |
| Journal | Radiology |
| Volume | 307 |
| Issue number | 1 |
| Early online date | 10 Jan 2023 |
| DOIs | |
| Publication status | Published - 1 Apr 2023 |
| Externally published | Yes |
Bibliographical note
Funding Information:Supported by Patient-Centered Outcomes Research Institute (PCS-1505-30497), PRECISION (Cancer Research UK, KWF Kankerbestrijding, ref. C38317/A24043), and National Institutes of Health (R00-CA207872).
Funding Information:
Disclosures of conflicts of interest: D.B. Employed by Vara after manuscript submission. S.M.T. No relevant relationships. C.N.R. No relevant relationships. T.L. No relevant relationships. A.M. No relevant relationships. A.B.F. No relevant relationships. E.S.F. On the DataSafety Monitoring Board for the ISPY-2 trial. A.H.P. Royalties from UpToDate for coauthoring a chapter on breast cancer survivorship. A.M.T. No relevant relationships. V.P.R. No relevant relationships. W.H.v.H. Grants from the Royal Cancer Society/Koningin Wilhelmina Fonds; member of the OECI Accreditation and Designation Board; Chair of the OECI Working Group Health Economics. L.J.G. Grants from the Department of Defense and the National Institutes of Health; consulting fees from Hologic and Medscape Reference. T.H. No relevant relationships. E.S.H. On the DataSafety Monitoring Board of Merck and AstraZeneca; on the NIH NCI Breast Cancer Steering Committee. M.D.R. No relevant relationships.
Publisher Copyright:
© RSNA, 2023.
